A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical TrialSai‐Hong Ignatius Ou, Trever G. Bivona, Kimmie Ng et al.|Journal of Thoracic Oncology|2020Cited by 74
Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentPasi A. Jänne, Melissa L. Johnson, Frédéric Bigot et al.|Molecular Cancer Therapeutics|2023Cited by 60
Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signalingJohanna C. Bendell, S.‐H.I. Ou, Susanna V. Ulahannan et al.|European Journal of Cancer|2020Cited by 27
Abstract LB001: Anti-tumor activity and tolerability of the SHP2 inhibitor RMC-4630 as a single agent in patients with RAS-addicted solid cancersMarianna Koczywas, Sai‐Hong Ignatius Ou, Eric B. Haura et al.|Cancer Research|2021Cited by 16
Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical studyJosie Hayes, Eric B. Haura, Marianna Koczywas et al.|Cancer Research|2021Cited by 4